Browsing Tag
in vivo study
1 post
Argent Biopharma (ASX: RGT) shares rise 7.69% as U.S. in vivo study validates ArtemiC efficacy in Alzheimer’s model
Argent Biopharma gains 7.69% after U.S. in vivo Alzheimer’s study validates ArtemiC’s plaque-reducing effects. Read more on RGT’s strategy and market outlook.